AviadoBioTM Raises $80 million in Collection A Funding to Progress Neurodegenerative Gene Therapy Platform
-
Collection A led by New Organization Associates (NEA) and co-led by Monograph Cash follows seeding by Advent Daily life Sciences, Dementia Discovery Fund (DDF), F-Key Money, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc
-
AviadoBio’s special platform brings together future-technology gene therapy layout with deep neuroscience knowledge and a novel neuroanatomy-led strategy to drug shipping
-
Co-founded by top neurologist and neuroscientist Professor Christopher Shaw, molecular neurobiologist Dr Youn Bok Lee and vector biologist Dr Do Young Lee from King’s Faculty London and the United kingdom Dementia Investigate Institute
-
Lisa Deschamps appointed Chief Executive Officer, bringing 25 several years of industry and substantial gene therapy encounter
London, Uk, December 2, 2021 — AviadoBio Ltd, a revolutionary gene treatment organization concentrated on acquiring and delivering transformative medications for people dwelling with neurodegenerative problems, declared now the thriving completion of an $80 million (£58.6 million) Sequence A financing round, next an preliminary $16.5 million (£12 million) seed funding. The money will be made use of to progress AviadoBio’s direct software in frontotemporal dementia (FTD) into the clinic, development its preclinical belongings, including for amyotrophic lateral sclerosis (ALS), while continuing to develop its field-primary team.
The funding was led by New Company Associates (NEA) and co-led by Monograph Money, with participation from LSP, as nicely as seed traders Arrival Lifestyle Sciences, Dementia Discovery Fund (DDF), F-Key Capital, JJDC and clinical study charity LifeArc.
AviadoBio’s technology was designed in the laboratory of Christopher Shaw, Professor of Neurology and Neurogenetics at King’s College or university London’s Institute of Psychiatry, Psychology & Neuroscience, with the guidance of the Uk Dementia Study Institute, the My Name’5 Doddie Basis and the Van Geest Foundation and, incubated by F-Prime Funds and JJDC.
“Whilst neurodegenerative ailments are focal at onset, the pathology finally spreads all through the anxious procedure. We have seen that modifying gene expression can be healing, but attaining widespread distribution is the biggest problem. We have proven that precision micro dosing to neural networks will produce wide CNS expression, furnishing secure and productive therapies,” stated Prof. Christopher Shaw, Co-founder and Main Scientific and Medical Advisor of AviadoBio. “We are instantly exploiting insights into the leads to of conditions to style and design therapies that have the opportunity to heal sufferers for whom there are no efficient treatment options. I imagine that AviadoBio has the probable to transfer neurodegeneration from palliation to prevention.”
Shaw additional: “AviadoBio’s special system combines up coming-generation gene treatment design with deep neuroscience skills and a novel neuroanatomy-led approach to drug supply. Precision micro dosing achieves intensive gene expression through the anxious process, maximizing the therapeutic prospective for sufferers residing with devastating neurological diseases.”
The Enterprise is led by not too long ago appointed Chief Government Officer and Board member Lisa Deschamps, former Senior Vice President and Main Business Officer at Novartis Gene Therapies. Lisa delivers a lot more than 25 several years of biopharma expertise like main the worldwide neuroscience enterprise of Novartis and the all over the world commercialization of its gene treatment for spinal muscular atrophy.
“I am fired up about the assure we can bring to persons dwelling with neurodegenerative illness, in which a sizeable unmet professional medical require continues to be with only symptomatic therapies currently available. Our differentiated method has the possible to transform the treatment method landscape and we have the option with our group of experienced investors, our advisors and founders, to adjust the life of folks living with these debilitating situations,” explained Lisa Deschamps, Main Executive Officer. “The enlargement of our team and trader syndicate, positions AviadoBio to make this mission a reality although advancing the industry.”
As element of the Collection A funding, Matt McAviney, Husband or wife at NEA and Tim Funnell, Partner at Monograph Funds have been appointed to the Company’s Board of Directors. They are joined by Amber Salzman and Prof. Philip Scheltens as an unbiased Board Director and a Board Observer for LSP, respectively. Amber has been a revolutionary entrepreneur in foremost firms and not-for-financial gain organizations centered on gene therapies and rare illnesses for more than 20 many years, while Prof. Sheltens is a environment-renowned dementia scientist and considered chief.
“Traditionally, there have been quite handful of selections to combat the devastating study course of neurodegenerative disorders,” reported Matt McAviney, Lover, NEA and AviadoBio Board member. “AviadoBio’s gene treatment platform introduces a groundbreaking tactic, supported by world-renowned neuroscience skills and strong preclinical details. The Organization is poised to make a meaningful impression, and we are thrilled to spouse with the crew to introduce a new portfolio of treatment options to patients suffering from a array of debilitating disorders.”
About AviadoBio
At AviadoBio our mission is to completely transform the life of men and women residing with neurodegenerative diseases by acquiring and providing transformative gene therapies for ailments such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technological innovation is dependent on revolutionary analysis from King’s College or university London and the United kingdom Dementia Investigation Institute, co-started by Prof. Christopher Shaw, Dr. Youn Bok Lee and Dr. Do Younger Lee, with support from primary lifestyle science investors and Dr. Jonathan Jones and Dr. Graeme Fielder, as the Company’s founding management crew. AviadoBio is making entire world-course capabilities to discover, build, manufacture and commercialize gene treatment products and solutions. For much more details, please pay a visit to www.aviadobio.com and comply with us at Twitter @AviadoBio and LinkedIn AviadoBio.
Call:
For media enquiries:
Consilium Strategic Communications
Chris Gardner, Angela Gray, Isabelle Abdou
+44 () 20 3709 5700
[email protected]
